ViewRay, Inc. (Nasdaq: VRAY) announced today that Edogawa Hospital in Tokyo is 
the first hospital in Japan to treat patients with the MRIdian Linac System. 
Edogawa Hospital began treating patients in 2018 on the MRIdian cobalt system. 
The upgrade to MRIdian Linac combines MRI-guidance with a linear accelerator 
for faster and more accurate delivery of radiation therapy.  

"I am very pleased that Edogawa Hospital has the first MRIdian Linac in Japan. 
With this system, we can shorten the treatment time not only for our focused 
treatment areas such as pancreatic and lung cancers, but we can also treat 
patients with a wider range of cancers," said Dr. Yukihiro Hama, Head of the 
Department of Radiation Oncology at Edogawa Hospital.  "In addition to local 
Japanese patients, we have been actively treating foreign patients and believe 
that MRIdian Linac will enable us to contribute to society more effectively by 
improving patients' quality of life."

Unlike conventional radiation therapy systems, MRIdian combines MR imaging and 
radiation therapy in one system. This combination allows physicians to define 
treatment margins based on MR images of patient anatomy in support of the 
delivery of safe and effective radiotherapy -- including stereotactic body 
radiation therapy (SBRT), which utilizes ablative, high-doses in five or fewer 
treatment sessions. MRIdian enables continuous tracking of the target and 
surrounding soft tissues without fiducial markers, adaptation of therapy in 
response to daily anatomical changes, and automatic pausing of the radiation 
(beam gating) if the target moves outside of the user-defined boundary. This 
allows for delivery of the prescribed dose to the target while sparing 
surrounding healthy tissue and critical structures, potentially minimizing 
toxicities typically associated with radiation therapy.

Previously, ViewRay announced that the company had received Shonin approval 
from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the 
MRIdian Linac System featuring a linear accelerator (Linac) for beam delivery. 
Its predecessor, the MRIdian cobalt system, was the first MRI-guided radiation 
therapy system to receive Shonin approval in Japan in August 2016. Subsequently 
two MRIdian cobalt systems were installed at Edogawa Hospital and the National 
Cancer Center Japan.

ViewRay is represented in Japan by ITOCHU Corporation, one of the two largest 
general trading companies in Japan. ITOCHU has been focusing on the healthcare 
business to promote important medical innovations in Japan for approximately 40 
years.

Currently, 41 MRIdian systems are installed at hospitals around the world where 
they are used to treat a wide variety of solid tumors and are the focus of 
numerous ongoing research efforts. MRIdian has been the subject of hundreds of 
peer-reviewed publications, scientific meeting abstracts, and presentations. 
More than 11,000 patients have been treated with MRIdian. For a list of 
treatment centers, please visit: 
https://viewray.com/find-mridian-mri-guided-radiation-therapy/

About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian 
radiation therapy system. MRIdian is built upon a proprietary high-definition 
MR imaging system designed from the ground up to address the unique challenges 
and clinical workflow for advanced radiation oncology. Unlike MR systems used 
in diagnostic radiology, MRIdian's high-definition MR was purpose built to 
address specific challenges, including beam distortion, skin toxicity, and 
other concerns that potentially may arise when high magnetic fields interact 
with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, 
Inc. 

ViewRay is a medical device manufacturer and cannot and does not recommend 
specific treatment approaches. Individual results may vary. The results 
described herein may not be predictive 

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of 
Section 27A of the Private Securities Litigation Reform Act. Statements in this 
press release that are not purely historical are forward-looking statements. 
Such forward-looking statements include, among other things, the rate of new 
orders, upgrades, and installations, ViewRay's anticipated future operating and 
financial performance, and ViewRay's conference calls to discuss its quarterly 
results. Actual results could differ from those projected in any 
forward-looking statements due to numerous factors. Such factors include, among 
others, the ability to commercialize MRIdian Linac System, demand for ViewRay's 
products, the ability to convert backlog into revenue, the timing of delivery 
of ViewRay's products, the timing, length, and severity of the recent COVID-19 
(coronavirus) pandemic, including its impacts across our businesses on demand, 
operations and our global supply chains, the results and other uncertainties 
associated with clinical trials, the ability to raise the additional funding 
needed to continue to pursue ViewRay's business and product development plans, 
the inherent uncertainties associated with developing new products or 
technologies, competition in the industry in which ViewRay operates, and 
overall market conditions. For a further description of the risks and 
uncertainties that could cause actual results to differ from those expressed in 
these forward-looking statements, as well as risks relating to ViewRay's 
business in general, see ViewRay's current and future reports filed with the 
Securities and Exchange Commission, including its Annual Report on Form 10-K 
for the fiscal year ended December 31, 2019 and its Quarterly Reports on Form 
10-Q, as updated periodically with the company's other filings with the SEC. 
These forward-looking statements are made as of the date of this press release, 
and ViewRay assumes no obligation to update the forward-looking statements, or 
to update the reasons why actual results could differ from those projected in 
the forward-looking statements, except as required by law. 

SOURCE: ViewRay, Inc.

CONTACT: Media Enquiries: Karen Hackstaff, Vice President, Strategy and Brand, 
ViewRay, Inc., 1-844-MRIdian (674-3426), media@viewray.com, Investor Relations: 
Michaella Gallina, Vice President, Chief of Staff, Head of Investor Relations 
and Communications, ViewRay, Inc., 1-844-MRIdian (674-3426), 
investors@viewray.com